• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol 
    •   QMRO Home
    • Blizard Institute
    • Centre for Cell Biology and Cutaneous Research
    • Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol
    •   QMRO Home
    • Blizard Institute
    • Centre for Cell Biology and Cutaneous Research
    • Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Gastric output of pancreatic secretory trypsin inhibitor is increased by misoprostol

    View/Open
    PLAYFORDGastricOutput1991FINAL.pdf (1004.Kb)
    Volume
    32
    Pagination
    1396 - 1400
    Publisher
    BMJ
    Publisher URL
    http://gut.bmj.com/
    DOI
    10.1136/gut.32.11.1396
    Journal
    Gut
    Metadata
    Show full item record
    Abstract
    Pancreatic secretory trypsin inhibitor (PSTI) is a potent protease inhibitor that also has growth promoting activity. It has recently been identified in the foveolar cells of the stomach, which secrete mucus. We examined the effects of the prostaglandin E1 analogue misoprostol on gastric PSTI output. Seven normal volunteers took part. An initial period ofgastric aspiration was followed by four 40 minute periods of gastric perfusion at 5 ml/minute of: 0-14 molll saline, 0.17 mmol/l bicarbonate, bicarbonate with misoprostol 400 rig, and then bicarbonate again. All perfusates contained polyethylene glycol 4000 as a marker. Misoprostol increased median gastric secretion of PSTI from 11 to 33 ig/hour (p<005), producing concentrations in gastric juice six times higher than those found in jejunal juice and about 1/30 of the values seen in pancreatic juice. Median mucus secretion increased to a lesser extent from 29 to 38 mg/hour during misoprostol. There was no change in intragastric concentrations of protein or of epidermal growth factor during infusion of misoprostol. Infusion of pentagastrin (6 iglkg/ hour) had no effect on gastric secretion of mucus, PSTI, or protein. Human gastric mucus was degraded on incubation with trypsin in vitro and this was prevented by the addition of PSTI. These results suggest that gastric PSTI may protect the gastric mucus layer against refluxed pancreatic proteases. Increased output of PSTI during microprostol may contribute to the protective effect of this drug.
    Authors
    Playford, RJ; Batten, JJ; Freeman, TC; Beardsall, K; Vesey, DA; Fenn, GC; Baron, JH; Baron, JH; Calam, J
    URI
    https://qmro.qmul.ac.uk/xmlui/handle/123456789/159
    Collections
    • Centre for Cell Biology and Cutaneous Research [361]
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.